MG
DNLI icon

Marex Group’s Denali Therapeutics DNLI Stock Holding History

Marex Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.6M Buy
295,631
+8,631
+3% +$177K 0.03% 204
2026
Q1 		$5.51M Sell
287,000
-1
-0% -$20 0.03% 210
2025
Q4 		$4.74M Sell
287,001
-3,999
-1% -$67.5K 0.03% 224
2025
Q3 		$4.23M Buy
291,000
+29,000
+11% +$417K 0.03% 203
2025
Q2 		$3.67M Buy
+262,000
New +$3.69M 0.03% 183

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's DNLI Position: Q2 2026 in Review

Marex Group increased its Denali Therapeutics (DNLI) stake by 3% in Q2 2026, buying an estimated $177K and bringing the position to 295,631 shares worth $7.6M. The position accounts for 0.03% of the portfolio, ranked #204.

Marex Group first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Marex Group held 295,631 shares of Denali Therapeutics worth $7.6M as of Q2 2026.
  • Marex Group bought 8,631 Denali Therapeutics shares in Q2 2026, an estimated $177K.
  • Denali Therapeutics made up 0.03% of Marex Group's portfolio in Q2 2026, its #204 holding.
  • Marex Group first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.